How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "8357"
  ["article_id"]=>
  string(4) "8357"
  [1]=>
  string(81) "Coloplast A/S - Transactions in connection with share buy-back programme, week 11"
  ["article_title"]=>
  string(81) "Coloplast A/S - Transactions in connection with share buy-back programme, week 11"
  [2]=>
  string(123) "As mentioned in Announcement no. 02/2020 Coloplast is initiating a share buyback programme totalling up to DKK 500 million."
  ["short_description"]=>
  string(123) "As mentioned in Announcement no. 02/2020 Coloplast is initiating a share buyback programme totalling up to DKK 500 million."
  [3]=>
  string(134) "
As mentioned in Announcement no. 02/2020 Coloplast is initiating a share buyback programme totalling up to DKK 500 million.
"
  ["description"]=>
  string(134) "
As mentioned in Announcement no. 02/2020 Coloplast is initiating a share buyback programme totalling up to DKK 500 million.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "27"
  ["rss_id"]=>
  string(2) "27"
  [14]=>
  string(149) "http://www.globenewswire.com/news-release/2020/03/16/2000967/0/en/Coloplast-A-S-Transactions-in-connection-with-share-buy-back-programme-week-11.html"
  ["blog_url"]=>
  string(149) "http://www.globenewswire.com/news-release/2020/03/16/2000967/0/en/Coloplast-A-S-Transactions-in-connection-with-share-buy-back-programme-week-11.html"
  [15]=>
  string(19) "2020-03-16 19:42:00"
  ["add_date"]=>
  string(19) "2020-03-16 19:42:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:15"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:15"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Coloplast A/S - Transactions in connection with share buy-back programme, week 11

As mentioned in Announcement no. 02/2020 Coloplast is initiating a share buyback programme totalling up to DKK 500 mi

array(40) {
  [0]=>
  string(4) "8358"
  ["article_id"]=>
  string(4) "8358"
  [1]=>
  string(78) "Coloplast A/S - Transaktioner i henhold til aktietilbagekøbsprogram, uge 11"
  ["article_title"]=>
  string(78) "Coloplast A/S - Transaktioner i henhold til aktietilbagekøbsprogram, uge 11"
  [2]=>
  string(133) "Som meddelt i Selskabsmeddelelse nr. 02/2020 har Coloplast iværksat et tilbagekøbsprogram på i alt 500 millioner kroner. "
  ["short_description"]=>
  string(133) "Som meddelt i Selskabsmeddelelse nr. 02/2020 har Coloplast iværksat et tilbagekøbsprogram på i alt 500 millioner kroner. "
  [3]=>
  string(144) "
Som meddelt i Selskabsmeddelelse nr. 02/2020 har Coloplast iværksat et tilbagekøbsprogram på i alt 500 millioner kroner. 
"
  ["description"]=>
  string(144) "
Som meddelt i Selskabsmeddelelse nr. 02/2020 har Coloplast iværksat et tilbagekøbsprogram på i alt 500 millioner kroner. 
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "27"
  ["rss_id"]=>
  string(2) "27"
  [14]=>
  string(148) "http://www.globenewswire.com/news-release/2020/03/16/2000967/0/da/Coloplast-A-S-Transaktioner-i-henhold-til-aktietilbagek%C3%B8bsprogram-uge-11.html"
  ["blog_url"]=>
  string(148) "http://www.globenewswire.com/news-release/2020/03/16/2000967/0/da/Coloplast-A-S-Transaktioner-i-henhold-til-aktietilbagek%C3%B8bsprogram-uge-11.html"
  [15]=>
  string(19) "2020-03-16 19:42:00"
  ["add_date"]=>
  string(19) "2020-03-16 19:42:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:15"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:15"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Coloplast A/S - Transaktioner i henhold til aktietilbagekøbsprogram, uge 11

Som meddelt i Selskabsmeddelelse nr. 02/2020 har Coloplast iværksat et tilbagekøbsprogram på i alt 500 milli

array(40) {
  [0]=>
  string(4) "8404"
  ["article_id"]=>
  string(4) "8404"
  [1]=>
  string(94) "BY-HEALTH’s annual revenue up 21% but Australian subsidiary hurt by new e-commerce laws"
  ["article_title"]=>
  string(94) "BY-HEALTH’s annual revenue up 21% but Australian subsidiary hurt by new e-commerce laws"
  [2]=>
  string(154) "Chinese health foods giant BY-HEALTH's FY19 revenue jumped 20.94% to hit RMB$5.2bn (US$748m), however performance from its Australian subsidiary Life-"
  ["short_description"]=>
  string(154) "Chinese health foods giant BY-HEALTH's FY19 revenue jumped 20.94% to hit RMB$5.2bn (US$748m), however performance from its Australian subsidiary Life-"
  [3]=>
  string(232) "Chinese health foods giant BY-HEALTH's FY19 revenue jumped 20.94% to hit RMB$5.2bn (US$748m), however performance from its Australian subsidiary Life-Space failed to meet expectations due to changes in Chinaâs e-commerce law."
  ["description"]=>
  string(232) "Chinese health foods giant BY-HEALTH's FY19 revenue jumped 20.94% to hit RMB$5.2bn (US$748m), however performance from its Australian subsidiary Life-Space failed to meet expectations due to changes in Chinaâs e-commerce law."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "35"
  ["rss_id"]=>
  string(2) "35"
  [14]=>
  string(195) "https://www.nutraingredients-asia.com/Article/2020/03/16/BY-HEALTH-s-annual-revenue-up-21-but-Australian-subsidiary-hurt-by-new-e-commerce-laws?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(195) "https://www.nutraingredients-asia.com/Article/2020/03/16/BY-HEALTH-s-annual-revenue-up-21-but-Australian-subsidiary-hurt-by-new-e-commerce-laws?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2020-03-16 09:22:00"
  ["add_date"]=>
  string(19) "2020-03-16 09:22:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:26"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:26"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

BY-HEALTH’s annual revenue up 21% but Australian subsidiary hurt by new e-commerce

Chinese health foods giant BY-HEALTH's FY19 revenue jumped 20.94% to hit RMB$5.2bn (US$748m), however performance fr

array(40) {
  [0]=>
  string(4) "8568"
  ["article_id"]=>
  string(4) "8568"
  [1]=>
  string(113) "Sanofi and Regeneron Begin Global Kevzara® (sarilumab) Clinical Trial Program in Patients with Severe COVID-19"
  ["article_title"]=>
  string(113) "Sanofi and Regeneron Begin Global Kevzara® (sarilumab) Clinical Trial Program in Patients with Severe COVID-19"
  [2]=>
  string(150) "CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 16, 2020 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc today announced the"
  ["short_description"]=>
  string(150) "CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 16, 2020 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc today announced the"
  [3]=>
  string(252) "CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 16, 2020 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc today announced they have started a clinical program evaluating Kevzara® (sarilumab) in patients hospitalized..."
  ["description"]=>
  string(252) "CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 16, 2020 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc today announced they have started a clinical program evaluating Kevzara® (sarilumab) in patients hospitalized..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/sanofi-regeneron-begin-global-kevzara-sarilumab-clinical-trial-program-patients-severe-covid-19-18496.html?utm_source=ddc&utm_medium=rss&utm_campaign=Sanofi+and+Regeneron+Begin+Global+Kevzara%C2%AE+%28sarilumab%29+Clinical+Trial+Program+in+Patients+with+Severe+C"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/sanofi-regeneron-begin-global-kevzara-sarilumab-clinical-trial-program-patients-severe-covid-19-18496.html?utm_source=ddc&utm_medium=rss&utm_campaign=Sanofi+and+Regeneron+Begin+Global+Kevzara%C2%AE+%28sarilumab%29+Clinical+Trial+Program+in+Patients+with+Severe+C"
  [15]=>
  string(19) "2020-03-16 09:03:22"
  ["add_date"]=>
  string(19) "2020-03-16 09:03:22"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:05"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:05"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Sanofi and Regeneron Begin Global Kevzara® (sarilumab) Clinical Trial Program in Patien

CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 16, 2020 /PRNewswire/ -- Sanofi and Regeneron Pharmaceut

array(40) {
  [0]=>
  string(4) "8414"
  ["article_id"]=>
  string(4) "8414"
  [1]=>
  string(67) "UC San Diego Health Develops COVID-19 Test, Begins Testing Patients"
  ["article_title"]=>
  string(67) "UC San Diego Health Develops COVID-19 Test, Begins Testing Patients"
  [2]=>
  string(150) "The UC San Diego Health System has developed a diagnostic test that can determine whether a patient has contracted the novel coronavirus in about eigh"
  ["short_description"]=>
  string(150) "The UC San Diego Health System has developed a diagnostic test that can determine whether a patient has contracted the novel coronavirus in about eigh"
  [3]=>
  string(353) "The UC San Diego Health System has developed a diagnostic test that can determine whether a patient has contracted the novel coronavirus in about eight hours. Developed under guidance that the FDA published roughly two weeks ago amid the severe shortage of tests for the viral illness, COVID-19, UCSD Health developed and validated an in-house […]"
  ["description"]=>
  string(353) "The UC San Diego Health System has developed a diagnostic test that can determine whether a patient has contracted the novel coronavirus in about eight hours. Developed under guidance that the FDA published roughly two weeks ago amid the severe shortage of tests for the viral illness, COVID-19, UCSD Health developed and validated an in-house […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(108) "https://xconomy.com/san-diego/2020/03/14/uc-san-diego-health-develops-covid-19-test-begins-testing-patients/"
  ["blog_url"]=>
  string(108) "https://xconomy.com/san-diego/2020/03/14/uc-san-diego-health-develops-covid-19-test-begins-testing-patients/"
  [15]=>
  string(19) "2020-03-14 13:47:19"
  ["add_date"]=>
  string(19) "2020-03-14 13:47:19"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:27"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

UC San Diego Health Develops COVID-19 Test, Begins Testing Patients

The UC San Diego Health System has developed a diagnostic test that can determine whether a patient has contracted the n

array(40) {
  [0]=>
  string(4) "8340"
  ["article_id"]=>
  string(4) "8340"
  [1]=>
  string(77) "FDA Spells Out Challenges for Sponsors of Therapies for Certain Rare Diseases"
  ["article_title"]=>
  string(77) "FDA Spells Out Challenges for Sponsors of Therapies for Certain Rare Diseases"
  [2]=>
  string(153) "&#nl        The FDA detailed how sponsors can support the effectiveness of investigational new drugs or new drug uses for treatment of certain rare disea"
  ["short_description"]=>
  string(153) "&#nl        The FDA detailed how sponsors can support the effectiveness of investigational new drugs or new drug uses for treatment of certain rare disea"
  [3]=>
  string(204) "&#nl        The FDA detailed how sponsors can support the effectiveness of investigational new drugs or new drug uses for treatment of certain rare diseases, in final guidance published Friday. &#nl      "
  ["description"]=>
  string(204) "&#nl        The FDA detailed how sponsors can support the effectiveness of investigational new drugs or new drug uses for treatment of certain rare diseases, in final guidance published Friday. &#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(117) "https://www.fdanews.com/articles/196246-fda-spells-out-challenges-for-sponsors-of-therapies-for-certain-rare-diseases"
  ["blog_url"]=>
  string(117) "https://www.fdanews.com/articles/196246-fda-spells-out-challenges-for-sponsors-of-therapies-for-certain-rare-diseases"
  [15]=>
  string(19) "2020-03-14 06:16:00"
  ["add_date"]=>
  string(19) "2020-03-14 06:16:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:28:54"
  ["create_at"]=>
  string(19) "2020-03-19 11:28:54"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA Spells Out Challenges for Sponsors of Therapies for Certain Rare Diseases

&#nl The FDA detailed how sponsors can support the effectiveness of investigational new drugs or new drug uses fo

array(40) {
  [0]=>
  string(4) "8341"
  ["article_id"]=>
  string(4) "8341"
  [1]=>
  string(57) "HHS Gives Liability Cover for Coronavirus Countermeasures"
  ["article_title"]=>
  string(57) "HHS Gives Liability Cover for Coronavirus Countermeasures"
  [2]=>
  string(136) "&#nl        HHS is providing immunity from legal liability for activities related to medical countermeasures against COVID-19.&#nl      "
  ["short_description"]=>
  string(136) "&#nl        HHS is providing immunity from legal liability for activities related to medical countermeasures against COVID-19.&#nl      "
  [3]=>
  string(136) "&#nl        HHS is providing immunity from legal liability for activities related to medical countermeasures against COVID-19.&#nl      "
  ["description"]=>
  string(136) "&#nl        HHS is providing immunity from legal liability for activities related to medical countermeasures against COVID-19.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(97) "https://www.fdanews.com/articles/196244-hhs-gives-liability-cover-for-coronavirus-countermeasures"
  ["blog_url"]=>
  string(97) "https://www.fdanews.com/articles/196244-hhs-gives-liability-cover-for-coronavirus-countermeasures"
  [15]=>
  string(19) "2020-03-14 06:12:16"
  ["add_date"]=>
  string(19) "2020-03-14 06:12:16"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:28:54"
  ["create_at"]=>
  string(19) "2020-03-19 11:28:54"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

HHS Gives Liability Cover for Coronavirus Countermeasures

&#nl HHS is providing immunity from legal liability for activities related to medical countermeasures against COV

array(40) {
  [0]=>
  string(4) "8377"
  ["article_id"]=>
  string(4) "8377"
  [1]=>
  string(50) "Alzheimer's and an unusual molecular chaperone"
  ["article_title"]=>
  string(50) "Alzheimer's and an unusual molecular chaperone"
  [2]=>
  string(83) "A research team elucidates the aggregation mechanism of the Alzheimer protein tau. "
  ["short_description"]=>
  string(83) "A research team elucidates the aggregation mechanism of the Alzheimer protein tau. "
  [3]=>
  string(83) "A research team elucidates the aggregation mechanism of the Alzheimer protein tau. "
  ["description"]=>
  string(83) "A research team elucidates the aggregation mechanism of the Alzheimer protein tau. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200313180829.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200313180829.htm"
  [15]=>
  string(19) "2020-03-14 06:08:29"
  ["add_date"]=>
  string(19) "2020-03-14 06:08:29"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:17"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:17"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Alzheimer's and an unusual molecular chaperone

A research team elucidates the aggregation mechanism of the Alzheimer protein tau. 

array(40) {
  [0]=>
  string(4) "8378"
  ["article_id"]=>
  string(4) "8378"
  [1]=>
  string(88) "Call for older people in poor countries to be considered in global responses to COVID-19"
  ["article_title"]=>
  string(88) "Call for older people in poor countries to be considered in global responses to COVID-19"
  [2]=>
  string(158) "Current guidance on coronavirus 'largely ignores' the implications for public health and clinical responses in light of those most at risk, according "
  ["short_description"]=>
  string(158) "Current guidance on coronavirus 'largely ignores' the implications for public health and clinical responses in light of those most at risk, according "
  [3]=>
  string(210) "Current guidance on coronavirus 'largely ignores' the implications for public health and clinical responses in light of those most at risk, according to an international group of global health experts. "
  ["description"]=>
  string(210) "Current guidance on coronavirus 'largely ignores' the implications for public health and clinical responses in light of those most at risk, according to an international group of global health experts. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200313155256.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200313155256.htm"
  [15]=>
  string(19) "2020-03-14 03:52:56"
  ["add_date"]=>
  string(19) "2020-03-14 03:52:56"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:17"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:17"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Call for older people in poor countries to be considered in global responses to COVID-19

Current guidance on coronavirus 'largely ignores' the implications for public health and clinical responses in l

array(40) {
  [0]=>
  string(4) "8415"
  ["article_id"]=>
  string(4) "8415"
  [1]=>
  string(67) "Lax Approval Requirements Yield Blockbusters That Don’t Work"
  ["article_title"]=>
  string(67) "Lax Approval Requirements Yield Blockbusters That Don’t Work"
  [2]=>
  string(165) "With the backdrop of Biogen’s BLA filing, and the FDA’s expected response for aducanumab in Alzheimer’s disease in 2020, the link between effica"
  ["short_description"]=>
  string(165) "With the backdrop of Biogen’s BLA filing, and the FDA’s expected response for aducanumab in Alzheimer’s disease in 2020, the link between effica"
  [3]=>
  string(398) "With the backdrop of Biogen’s BLA filing, and the FDA’s expected response for aducanumab in Alzheimer’s disease in 2020, the link between efficacy and approval seems to have broken. Conditional FDA approvals can’t help when the conditions are ignored. I met the management of InterMune almost 20 years ago when it was a mid-sized US biotechnology company […]"
  ["description"]=>
  string(398) "With the backdrop of Biogen’s BLA filing, and the FDA’s expected response for aducanumab in Alzheimer’s disease in 2020, the link between efficacy and approval seems to have broken. Conditional FDA approvals can’t help when the conditions are ignored. I met the management of InterMune almost 20 years ago when it was a mid-sized US biotechnology company […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(100) "https://xconomy.com/national/2020/03/13/lax-approval-requirements-yield-blockbusters-that-dont-work/"
  ["blog_url"]=>
  string(100) "https://xconomy.com/national/2020/03/13/lax-approval-requirements-yield-blockbusters-that-dont-work/"
  [15]=>
  string(19) "2020-03-14 00:23:38"
  ["add_date"]=>
  string(19) "2020-03-14 00:23:38"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:27"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Lax Approval Requirements Yield Blockbusters That Don’t Work

With the backdrop of Biogen’s BLA filing, and the FDA’s expected response for aducanumab in Alzheimerâ€

array(40) {
  [0]=>
  string(4) "8333"
  ["article_id"]=>
  string(4) "8333"
  [1]=>
  string(63) "Acute coronary syndrome: risk factors, diagnosis and treatment "
  ["article_title"]=>
  string(63) "Acute coronary syndrome: risk factors, diagnosis and treatment "
  [2]=>
  string(145) "This overview describes the different management options for acute coronary syndrome and how pharmacists can support patients with the condition."
  ["short_description"]=>
  string(145) "This overview describes the different management options for acute coronary syndrome and how pharmacists can support patients with the condition."
  [3]=>
  string(145) "This overview describes the different management options for acute coronary syndrome and how pharmacists can support patients with the condition."
  ["description"]=>
  string(145) "This overview describes the different management options for acute coronary syndrome and how pharmacists can support patients with the condition."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "12"
  ["rss_id"]=>
  string(2) "12"
  [14]=>
  string(145) "https://www.pharmaceutical-journal.com/cpd-and-learning/cpd-article/acute-coronary-syndrome-risk-factors-diagnosis-and-treatment/20207744.article"
  ["blog_url"]=>
  string(145) "https://www.pharmaceutical-journal.com/cpd-and-learning/cpd-article/acute-coronary-syndrome-risk-factors-diagnosis-and-treatment/20207744.article"
  [15]=>
  string(19) "2020-03-13 23:45:00"
  ["add_date"]=>
  string(19) "2020-03-13 23:45:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:28:48"
  ["create_at"]=>
  string(19) "2020-03-19 11:28:48"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Acute coronary syndrome: risk factors, diagnosis and treatment

This overview describes the different management options for acute coronary syndrome and how pharmacists can support pat

array(40) {
  [0]=>
  string(4) "8471"
  ["article_id"]=>
  string(4) "8471"
  [1]=>
  string(102) "&#nlCOVID-19: developers of medicines or vaccines to benefit from free scientific advice, , 13/03/2020"
  ["article_title"]=>
  string(102) "&#nlCOVID-19: developers of medicines or vaccines to benefit from free scientific advice, , 13/03/2020"
  [2]=>
  string(168) "&#nl&#nl          &#nl              &#nl&#nl&#nlEMA provides full fee waivers for scientific advice applications from developers of potential therapeutics (to treat the"
  ["short_description"]=>
  string(168) "&#nl&#nl          &#nl              &#nl&#nl&#nlEMA provides full fee waivers for scientific advice applications from developers of potential therapeutics (to treat the"
  [3]=>
  string(196) "&#nl&#nl          &#nl              &#nl&#nl&#nlEMA provides full fee waivers for scientific advice applications from developers of potential therapeutics (to treat the disease) or vaccines (to..."
  ["description"]=>
  string(196) "&#nl&#nl          &#nl              &#nl&#nl&#nlEMA provides full fee waivers for scientific advice applications from developers of potential therapeutics (to treat the disease) or vaccines (to..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "88"
  ["rss_id"]=>
  string(2) "88"
  [14]=>
  string(104) "
https://www.ema.europa.eu/en/news/covid-19-developers-medicines-vaccines-benefit-free-scientific-advice"
  ["blog_url"]=>
  string(104) "
https://www.ema.europa.eu/en/news/covid-19-developers-medicines-vaccines-benefit-free-scientific-advice"
  [15]=>
  string(19) "2020-03-13 23:30:00"
  ["add_date"]=>
  string(19) "2020-03-13 23:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:35:01"
  ["create_at"]=>
  string(19) "2020-03-19 11:35:01"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

&#nlCOVID-19: developers of medicines or vaccines to benefit from free scientific advice,

&#nl&#nl &#nl &#nl&#nl&#nlEMA provides full fee waivers for scientific advice applications from de